Choose a date range

From To

Choose one or more categories


Show only original CenterWatch stories


Great Basin wins NIH grant to develop test for CRE superbug

Thursday, July 2, 2015 09:01 AM

The National Institute of Allergy and Infectious Diseases, part of the NIH, has awarded a research grant to Great Basin Scientific and Brigham Young University (BYU), to develop a rapid molecular diagnostic test direct from whole blood for carbapenem-resistant Enterobacteriaceae (CRE). The NIH research grant will play a key role in meeting the goals of President Obama's recent National Action Plan for Combating Antibiotic-Resistant Bacteria.

More... »

Quest Diagnostics

Baxalta launches focused on orphan diseases and underserved conditions

Thursday, July 2, 2015 08:53 AM

Baxalta has launched as a global biopharmaceutical company dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions. The company continues to advance in hematology and immunology and seeks to expand its oncology portfolio for patients with limited treatment options. Baxalta plans to launch 20 new products by 2020, leveraging the company’s existing global capabilities and footprint in more than 100 countries.

More... »

Entasis launches with a drug-resistant bacterial infections portfolio

Thursday, July 2, 2015 08:47 AM

Entasis Therapeutics, a Waltham, Mass.-based company, has launched with a portfolio of diverse, innovative investigational drugs for the treatment of serious drug-resistant bacterial infections.

More... »

PPD creates pediatric investigator network to enhance global trials capabilities

Wednesday, July 1, 2015 10:56 AM

Global CRO Pharmaceutical Product Development (PPD) has formalized relationships with eight investigator sites as part of a pediatric investigator network (PIN) the company has established to further enhance its pediatric clinical development capabilities.

More... »

Actelion creates Vaxxilon together with the Max Planck Society

Wednesday, July 1, 2015 10:38 AM

Actelion, a biopharmaceutical company based in Switzerland, has created a start-up, together with the Max Planck Society, in synthetic carbohydrate vaccines. The new company, Vaxxilon, aims to discover, develop, and commercialize synthetic carbohydrate vaccines.

More... »

Transgene plans restructuring to focus on R&D, cuts 120 jobs

Wednesday, July 1, 2015 10:21 AM

Transgene, a France-based biotechnology company specializing in immunotherapies for cancer and infectious diseases, plans to modify its vertical integration model and to implement a restructuring in order to maintain its competitiveness and to ensure a sustainable future.

More... »

AMAG Pharmaceuticals acquires Lumara Health's Maternal Health Business

Wednesday, July 1, 2015 10:20 AM

AMAG Pharmaceuticals, a Massachusetts-based specialty pharmaceutical company, has completed the acquisition of Lumara Health, a St. Louis, Mo.-based specialty pharmaceutical company with a particular focus on maternal health. The transaction was announced on September 29, 2014 and included upfront consideration of $600 million in cash and 3,209,971 shares of AMAG common stock, and additional contingent consideration of up to $350 million based on the achievement of sales milestones. 

More... »

Astrazeneca, University of Cambridge form joint Ph.D., clinical research scholarships

Wednesday, July 1, 2015 10:11 AM

AstraZeneca and the University of Cambridge have formed three new joint schemes to support more than 80 Ph.D. scholarships and eight clinical lectureships over the next five years, spanning translational science, basic and clinical research.

More... »

Celgene, Juno collaborate on cancer and autoimmune diseases

Wednesday, July 1, 2015 09:47 AM

Celgene, headquartered in Summit, N.J., and Seattle-based Juno Therapeutics have formed a global collaboration for the development and commercialization of immunotherapies. The two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on Chimeric Antigen Receptor Technology (CAR-T) and T Cell Receptor (TCR) technologies.

More... »

Eolas Therapeutics, AstraZeneca partner

Wednesday, July 1, 2015 09:30 AM

Eolas Therapeutics, a therapeutic development company based in Carlsbad, Calif., has entered into a worldwide license and partnership agreement with AstraZeneca on the Eolas Orexin-1 Receptor Antagonist (EORA) program for smoking cessation and other indications. The EORA program was awarded a Blueprint Neurotherapeutics (BPN) grant from the NIH for the development of the program from the preclinical stage through phase I clinical trials.

More... »


July 6

FDA sued by advocacy groups seeking hepatitis C trials data

Google to test health-tracking wristband to collect clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs